Clinical Trials · NCT01229943
Everolimus and Octreotide Acetate With or Without Bevacizumab in Treating Patients With Locally Advanced or Metastatic Pancreatic Neuroendocrine Tumors That Cannot Be Removed by Surgery
- Phase
- Phase 2
- Recruitment status
- Completed
- Sponsor
- National Cancer Institute (NCI)
- Enrollment
- 150
- Start date
- Oct 2010
- Locations
- 394 sites, United States, Canada
- Primary endpoint
- Progression Free Survival